Physician-neuroscientist and pharma medical director with 10+ years of translational research in academia and early clinical development. Board-certified in movement disorders and geriatric neurology with broad hands-on experience across multiple therapeutic areas, including Parkinson’s disease, Alzheimer’s disease, common and rare movement disorders (e.g. Huntington’s disease), epilepsy and sleep disorders. Doctor of Medicine (MD), Master in Epidemiology (MSc), Doctor of Philosophy (PhD) in Clinical Neuroscience and postdoctoral training in PET molecular imaging with a focus on genetics, preclinical and prodromal Parkinson’s disease. Designed, implemented and led several Phase 0, 1 and Phase 2 proof-of-concept trials in academia and in industry, with 90+ peer-reviewed publications in the field of common and rare movement disorders and dementias. Global regulatory experience with multiple interactions and face-to-face meetings (e.g. EMA, EunetHA, etc.). Servant leader encourages colleagues to step outside of their comfort zones and show intelligent disobedience, using a collaborative, inspiring, and empowering style and micromanage-free guidance.